Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

AZ and Regeneron will collaborate on finding small-molecule drugs directed against the GPR75 ... Novo Nordisk's once-daily injectable weight loss therapy Saxenda (liraglutide) has been a slow ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a condition in which breathing stops and starts repeatedly during sleep.

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.